Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T20:31:56.091Z.
Calculation as of: 2026-10-06T20:31:56.091Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$1.39B
EV/EBIT Ratio
29.39x
TTM Avg
29.70x
3Y Avg
32.28x
5Y Avg
57.69x
Market Cap
$1.42B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45B
EV/EBIT Ratio
9.98x
TTM Avg
25.95x
3Y Avg
23.59x
5Y Avg
24.10x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | N/A | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 29.39x | 29.70x | 32.28x | 57.69x |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 11.60x | 36.76x | 36.76x | 36.50x |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.44B | 204.05x | 79.44x | 108.81x | 130.77x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 9.98x | 25.95x | 23.59x | 24.10x |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | 5.99x | 5.99x | 5.99x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
